Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA4 | P22748 | 1/20 | 0.48 |
| ▸ | CA5A | P35218 | 1/20 | 0.48 |
| ▸ | CES2 | O00748 | 1/20 | 0.42 |
| ▸ | CES1 | P23141 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | PGK1 | P00558 | 2/20 | 0.33 |
| ▸ | PGK2 | P07205 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CFTR | P13569 | 1/20 | 0.33 |
| ▸ | PNP | P00491 | 1/20 | 0.33 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.33 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11324417 | 0.80 | TRPA1 (0.43) | CES2CES1TSHRTRPA1ALDH1A1 | |
| SCHEMBL5667423 | 0.80 | CA2 (0.52) | CA2CA4CA5ATSHRALDH1A1 | |
| SCHEMBL2171752 | 0.79 | CA2 (0.71) | CA2CA4CA5ATSHRALDH1A1 | |
| SCHEMBL3362601 | 0.78 | CA2 (0.50) | CA2CA4CA5ATSHRENPP1 | |
| SCHEMBL3364798 | 0.76 | PGK1 (0.55) | CES2CES1TSHRTRPA1ALDH1A1 | |
| SCHEMBL344618 | 0.76 | SMN1; SMN2 (0.52) | CA2CA4CA5ATSHRALDH1A1 | |
| SCHEMBL13538144 | 0.76 | CA2 (0.48) | CA2CA4CA5A | |
| Potassium Ion SCHEMBL10942524 | 0.76 | TRPA1 (0.40) | CES2CES1TSHRTRPA1ALDH1A1 | |
| SCHEMBL27152988 | 0.76 | TSHR (0.40) | CES2CES1TSHRTRPA1ALDH1A1 | |
| SCHEMBL7595631 | 0.76 | PGK1 (0.50) | CA2CA4CA5ATSHRTRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250041319-A1 | BICYCLIC HETEROARYL DERIVATIVES AS ECTONUCLEOTIDE PYROPHOSPHATASE PHOSPHODIESTERASE 1 INHIBITORS | RIBOSCIENCE LLC | 2025-02-06 | — | — | US | disclosed |
| US-12029744-B2 | Bicyclic heteroaryl derivatives as ectonucleotide pyrophosphatase phosphodiesterase 1 inhibitors | RIBOSCIENCE LLC (US) | 2024-07-09 | — | — | US | disclosed |
| EP-4249070-A2 | BICYCLIC HETEROARYL DERIVATIVES AS ECTONUCLEOTIDE PYROPHOSPHATASE PHOSPHODIESTERASE 1 INHIBITORS | Riboscience LLC (US) | 2023-09-27 | — | — | EP | disclosed |
| US-20220362266-A1 | BICYCLIC HETEROARYL DERIVATIVES AS ECTONUCLEOTIDE PYROPHOSPHATASE PHOSPHODIESTERASE 1 INHIBITORS | RIBOSCIENCE LLC | 2022-11-17 | — | — | US | disclosed |
| EP-3952995-A1 | BICYCLIC HETEROARYL DERIVATIVES AS ECTONUCLEOTIDE PYROPHOSPHATASE PHOSPHODIESTERASE 1 INHIBITORS | Riboscience LLC (US) | 2022-02-16 | — | — | EP | disclosed |
| CN-114040915-A | Bicyclic heteroaryl derivatives as ectonucleotide pyrophosphatase phosphodiesterase 1 inhibitors | 里伯赛恩斯有限责任公司 | 2022-02-11 | — | — | CN | disclosed |
| WO-2020210649-A1 | BICYCLIC HETEROARYL DERIVATIVES AS ECTONUCLEOTIDE PYROPHOSPHATASE PHOSPHODIESTERASE 1 INHIBITORS | RIBOSCIENCE LLC (US) | 2020-10-15 | — | — | WO | disclosed |
| US-9385332-B2 | Organic-inorganic hybrid multilayer gate dielectrics for thin film transistors | NORTHWESTERN UNIVERSITY (US) | 2016-07-05 | — | — | US | disclosed |
| US-20160072085-A1 | Organic-Inorganic Hybrid Multilayer Gate Dielectrics for Thin Film Transistors | NORTHWESTERN UNIVERSITY | 2016-03-10 | — | — | US | disclosed |
| US-9276226-B2 | Organic-inorganic hybrid multilayer gate dielectrics for thin-film transistors | NORTHWESTERN UNIVERSITY (US) | 2016-03-01 | — | — | US | disclosed |
| WO-2005064008-A9 | METHOD AND COMPOSITIONS FOR IDENTIFYING ANTI-HIV THERAPEUTIC COMPOUNDS | GILEAD SCIENCES INC (US) | 2006-09-28 | — | — | WO | disclosed |
| US-20050239054-A1 | Method and compositions for identifying anti-HIV therapeutic compounds | GILEAD SCIENCES. INC. | 2005-10-27 | — | — | US | disclosed |
| US-20050209197-A1 | Cellular accumulation of phosphonate analogs of HIV protease inhibitor compounds | GILEAD SCIENCES, INC. | 2005-09-22 | — | — | US | disclosed |
| WO-2005064008-A1 | METHOD AND COMPOSITIONS FOR IDENTIFYING ANTI-HIV THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2005-07-14 | — | — | WO | disclosed |
| EP-1509537-A2 | CELLULAR ACCUMULATION OF PHOSPHONATE ANALOGS OF HIV PROTEASE INHIBITOR COMPOUNDS AND THE COMPOUNDS AS SUCH | GILEAD SCIENCES, INC. (US) | 2005-03-02 | — | — | EP | disclosed |
| EP-1140980-B1 | PSEUDOPEPTIDE COMPOUNDS HAVING AN INHIBITING ACTIVITY WITH RESPECT TO PATHS ACTIVATED BY PROTEINS WITH ACTIVE TYROSINE KINASE ACTIVITY AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | INST NAT SANTE RECH MED (FR) | 2004-09-29 | — | — | EP | disclosed |
| WO-2003090690-A2 | CELLULAR ACCUMULATION OF PHOSPHONATE ANALOGS OF HIV PROTEASE INHIBITOR COMPOUNDS AND THE COMPOUNDS AS SUCH | GILEAD SCIENCES, INC. (US) | 2003-11-06 | — | — | WO | disclosed |
| US-20020055463-A1 | Pseudopeptide compounds having an inhibiting activity with respect to paths activated by proteins with active tyrosine kinase activity and pharmaceutical compositions containing same | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) (FR) | 2002-05-09 | — | — | US | disclosed |
| EP-1140980-A1 | PSEUDOPEPTIDE COMPOUNDS HAVING AN INHIBITING ACTIVITY WITH RESPECT TO PATHS ACTIVATED BY PROTEINS WITH ACTIVE TYROSINE KINASE ACTIVITY AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000039153-A1 | PSEUDOPEPTIDE COMPOUNDS HAVING AN INHIBITING ACTIVITY WITH RESPECT TO PATHS ACTIVATED BY PROTEINS WITH ACTIVE TYROSINE KINASE ACTIVITY AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE INSERM (FR) | 2000-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020055463-A1 | Pseudopeptide compounds having an inhibiting activity with respect to paths activated by proteins with active tyrosine kinase activity and pharmaceutical compositions containing same | ERBB2, CCNC, CDK1 | CA2 909/4885CA4 1128/4885CA5A 1057/4885 |
| US-20050209197-A1 | Cellular accumulation of phosphonate analogs of HIV protease inhibitor compounds | PPA1, PPME1, PNP | CA2 3935/4885CA4 3269/4885CA5A 3294/4885 |
| US-20050239054-A1 | Method and compositions for identifying anti-HIV therapeutic compounds | CES1, PNP, PGLS | CA2 3487/4885CA4 1030/4885CA5A 2188/4885 |
| US-20250041319-A1 | BICYCLIC HETEROARYL DERIVATIVES AS ECTONUCLEOTIDE PYROPHOSPHATASE PHOSPHODIESTERASE 1 INHIBITORS | ENPP1, ENPP3, SMPD1 | CA2 3193/4885CA4 4498/4885CA5A 1261/4885 |
| US-12029744-B2 | Bicyclic heteroaryl derivatives as ectonucleotide pyrophosphatase phosphodiesterase 1 inhibitors | ENPP1, ENPP3, SMPD1 | CA2 3208/4885CA4 4497/4885CA5A 1283/4885 |
| US-20220362266-A1 | BICYCLIC HETEROARYL DERIVATIVES AS ECTONUCLEOTIDE PYROPHOSPHATASE PHOSPHODIESTERASE 1 INHIBITORS | ENPP1, ENPP3, SMPD1 | CA2 3208/4885CA4 4497/4885CA5A 1283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.